跳至主要内容
临床试验/NCT04235257
NCT04235257进行中(未招募)4 期

Immunogenicity of Fractional Dose of the Bivalent and Nonavalent Intradermal HPV Vaccines.

University of Washington2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
进行中(未招募)
入组人数
40
试验地点
2
主要终点
HPV antibody detection after fractional HPV vaccination

研究概览

简要总结

This randomized phase IV trial compares fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, 12 months, and 24 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
27 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age 27-45 years at enrollment
  • Not intending to receive the HPV vaccine series for the duration of the study participation
  • Willing and able to provide written informed consent, undergo clinical evaluation, and adhere to follow-up schedule

排除标准

  • Prior immunization with HPV-vaccine (Cervarix, Gardasil-4, Gardasil-9)
  • Currently pregnant or breastfeeding
  • Immune deficiency or other immune disorder
  • HIV infection or continued high risk for HIV; patients at risk for HIV who do not have a negative HIV test in the last 6 months will be excluded
  • Cancer or chemotherapy (current, within 6 months, or anticipated in the future) except for fully excised non-melanoma skin cancer)
  • Unstable medical condition (e.g., malignant hypertension, poorly controlled diabetes,
  • Known allergy to vaccine components
  • Prior history of HPV-associated cancer

研究组 & 干预措施

Bivalent HPV vaccine

Experimental

One-fifth fractional dose (0.1 ml) of bivalent HPV vaccine administered subcutaneously

干预措施: HPV vaccine (Biological)

Nonavalent HPV vaccine

Experimental

One-fifth fractional dose (0.1 ml) of nonavalent HPV vaccine administered subcutaneously

干预措施: HPV vaccine (Biological)

结局指标

主要结局

HPV antibody detection after fractional HPV vaccination

时间窗: 12 months

HPV antibody response after delivery of a single, intradermal, fractional dose of the HPV-2 or HPV-9 vaccines

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anna Wald

Professor: School of Medicine

University of Washington

研究点 (2)

Loading locations...

相似试验